Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

shennong animal health (malaysia) sdn. bhd. - flubendazole -

Ireland - English - HPRA (Health Products Regulatory Authority)

elanco gmbh - flubendazole - oral powder - 50 milligram(s)/gram - flubendazole

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wsd agribusiness pty ltd - albendazole - oral solution/suspension - albendazole carbamate-benzimidazole active 19.0 g/l - parasiticides - goat | lamb | sheep | billy | buck | capra hircus | doe | ewe | hogget | kid | lamb | ovine | ram | weaner | wether - barber's pole worm-haemonchus contortus | black scour worm - trichostrongylus spp. | hookworm - bunostomum trigonocephalum | large bowel worm - o. venulosum | large lungworm - dictyocaulus filaria | large mouthed bowel worm | liver fluke | nodule worm - o. columbianum | small brown stomach worm-ostertagia spp. | small intestinal worm - cooperia spp. | stomach hair worm | tapeworm - moniezia spp. | thin necked intestinal worm | hair worm | intestinal hair worm | small hair worm | tapeworm - heads/segments | teladorsagia

United States - English - NLM (National Library of Medicine)

lineage therapeutics inc - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole is indicated for the treatment of the following infections: neurocysticercosis: albendazole is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . lesions considered responsive to albendazole therapy appear as nonenhancing cysts with no surrounding edema on contrast-enhanced computerized tomography. clinical studies in patients with lesions of this type demonstrate a 74% to 88% reduction in number of cysts; 40% to 70% of albendazole-treated patients showed resolution of all active cysts. hydatid disease: albendazole is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . this indication is based on combined clinical studies which demonstrated non-infectious cyst contents in approximately 80 to 90% of patients given albendazole for 3 cycles of therapy of 28 days each (see dosage and administration

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albendazole tablets are contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole tablets. risk summary based on findings from animal reproduction studies, albendazole may cause fetal harm when administered to a pregnant woman. however, available human data from a small number of published case series and reports on the use of multiple-dose albendazole in the 1st trimester of pregnancy, and several published studies on single-dose albendazole use later in pregnancy, have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in

United States - English - NLM (National Library of Medicine)

northstar rx llc. - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albendazole tablets are contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole tablets. risk summary based on findings from animal reproduction studies, albendazole may cause fetal harm when administered to a pregnant woman. however, available human data from a small number of published case series and reports on the use of multiple-dose albendazole in the 1st trimester of pregnancy, and several published studies on single-dose albendazole use later in pregnancy, have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wsd agribusiness pty ltd - fenbendazole - oral solution/suspension - fenbendazole carbamate-benzimidazole active 25.0 g/l - parasiticides - cattle | goat | sheep | beef | billy | bos indicus | bos taurus | bovine | buck | buffalo | bull | bullock | calf | capra hircus - barber's pole worm - haemonchus placei | barber's pole worm-haemonchus contortus | black scour worm - trichostrongylus spp. | large lungworm - dictyocaulus filaria | large mouthed bowel worm | lungworm - dictyocaulus viviparus | nodule worm - o. columbianum | nodule worm - oesophagostomum radiatum | small brown stomach worm-ostertagia spp. | small intestinal worm - cooperia spp. | tapeworm - monieza expansa | thin necked intestinal worm | threadworm - capillaria spp. | whipworm - trichuris ovis | whipworm - trichuris spp. | hair worm | intestinal hair worm | large lungworm | small hair worm | teladorsagia

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals - fenbendazole (unii: 621bvt9m36) (fenbendazole - unii:621bvt9m36) - fenbendazole 25 kg in 25 kg

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - albendazole - tablets - albendazole 400 mg - albendazole - albendazole - albendazole is indicated for the treatment of the following systemic helminth diseases: * echinococcosis (hydatid disease)albendazole is indicated for the treatment of liver, lung and peritoneal cysts. experience with bone cysts and those in the central nervous system and heart is limited. * cystic echinococcosis (caused by echinococcus granulosus)albendazole is used in patients with cystic echinococcosis:1. when surgical intervention is not feasible .2. as a co-adjunct to surgical treatment. 3. prior to surgical intervention. 4. if preoperative treatment was too short, if spillage has occurred or if viable cysts were found at surgery. 5. following percutaneous drainage of cysts for diagnostic or therapeutic reasons. * alveolar echinococcosis (caused by echinococcus multilocularis)although its efficacy has not been completely demonstrated in clinical trials, albendazole is used in patients with alveolar echinococcosis in the following situations:1. in inoperable disease, particularly in cases of local or distant metastasis.2. following palliative surgery.3. following radical surgery or liver transplantation.

United States - English - NLM (National Library of Medicine)

cipla usa inc. - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albendazole tablets are indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albendazole tablets are contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albendazole tablets. risk summary based on findings from animal reproduction studies, albendazole may cause fetal harm when administered to a pregnant woman. however, available human data from a small number of published case series and reports on the use of multiple-dose albendazole in the 1st trimester of pregnancy, and several published studies on single-dose albendazole use later in pregnancy, have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in